Actinium Pharmaceuticals, Inc. is a pioneering clinical-stage biopharmaceutical company specializing in innovative therapies for bone marrow transplantation and adoptive cell therapies, primarily targeting hematologic malignancies. Headquartered in New York, the company is actively advancing its proprietary antibody-radionuclide conjugate platform, which seeks to enhance patient outcomes in transplantation and cancer treatment. With a robust pipeline and strategic partnerships, Actinium is positioned to address critical unmet medical needs in the oncology landscape.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

100 PARK AVENUE, NEW YORK, NY, UNITED STATES, 10017

December

$49.3 Million

-$44 Million

0.0

-1.31

$0.00

0.0%

-0.25